ARK Invest's position in ABSI, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKG | 10,810,521 | $98.8M | 5.00% | #6 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-11 | ARKG | Sell | Trimmed | 478,402 | $4.8M |
| 2026-10-26 | ARKG | Sell | Trimmed | 80,607 | $762K |
| 2026-07-23 | ARKG | Buy | Added | 4,753 | $38K |
| 2026-07-21 | ARKG | Buy | Added | 16,562 | $138K |
| 2026-07-20 | ARKG | Buy | Added | 15,996 | $131K |
| 2026-07-17 | ARKG | Buy | Added | 33,110 | $275K |
| 2026-07-16 | ARKG | Buy | Added | 314,467 | $2.6M |
| 2026-07-15 | ARKG | Sell | Trimmed | 5,694 | $56K |
| 2026-07-14 | ARKG | Sell | Trimmed | 3,446 | $35K |
| 2026-07-13 | ARKG | Sell | Trimmed | 3,262 | $33K |
| 2026-07-09 | ARKG | Sell | Trimmed | 37,406 | $429K |
| 2026-07-08 | ARKG | Sell | Trimmed | 591 | $7K |
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of…
See ABSI's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open ABSI on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.